Kymera Therapeutics Inc (NASDAQ: KYMR) is 90.69% higher on its value in year-to-date trading and has touched a low of $9.60 and a high of $48.70 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The KYMR stock was last observed hovering at around $46.50 in the last trading session, with the day’s gains setting it 2.05%.
Currently trading at $48.55, the stock is 12.58% and 25.35% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 0.67 million and changing 4.41% at the moment leaves the stock 45.31% off its SMA200. KYMR registered 138.81% gain for a year compared to 6-month gain of 25.55%.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The stock witnessed a 11.66% loss in the last 1 month and extending the period to 3 months gives it a 37.46%, and is 14.15% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 5.35% over the week and 6.96% over the month.
Kymera Therapeutics Inc (KYMR) has around 187 employees, a market worth around $3.00B and $88.55M in sales. Profit margin for the company is -178.27%. Distance from 52-week low is 405.73% and -0.31% from its 52-week high. The company has generated returns on investments over the last 12 months (-20.75%).
The EPS is expected to shrink by -16.28% this year
232.0 institutions hold shares in Kymera Therapeutics Inc (KYMR), with institutional investors hold 112.16% of the company’s shares. The shares outstanding are 55.59M, and float is at 55.34M with Short Float at 17.79%. Institutions hold 110.66% of the Float.
The top institutional shareholder in the company is PRICE T ROWE ASSOCIATES INC /MD/ with over 6.33 million shares valued at $254.55 million. The investor’s holdings represent 10.8489 of the KYMR Shares outstanding. As of 2024-03-31, the second largest holder is BAKER BROS. ADVISORS LP with 6.0 million shares valued at $241.04 million to account for 10.2731 of the shares outstanding. The other top investors are ATLAS VENTURE LIFE SCIENCE ADVISORS, LLC which holds 5.38 million shares representing 9.2133 and valued at over $216.17 million, while BVF INC/IL holds 8.8439 of the shares totaling 5.16 million with a market value of $207.5 million.
Kymera Therapeutics Inc (KYMR) Insider Activity
The most recent transaction is an insider sale by Gollob Jared, the company’s Chief Medical Officer. SEC filings show that Gollob Jared sold 23,145 shares of the company’s common stock on Jul 16 ’24 at a price of $45.81 per share for a total of $1.06 million. Following the sale, the insider now owns 95470.0 shares.
Kymera Therapeutics Inc disclosed in a document filed with the SEC on Jul 15 ’24 that Gollob Jared (Chief Medical Officer) sold a total of 16,455 shares of the company’s common stock. The trade occurred on Jul 15 ’24 and was made at $45.15 per share for $0.74 million. Following the transaction, the insider now directly holds 95740.0 shares of the KYMR stock.
Still, SEC filings show that on Jul 09 ’24, Booth Bruce (Director) disposed off 453,960 shares at an average price of $38.21 for $17.35 million. The insider now directly holds 723,246 shares of Kymera Therapeutics Inc (KYMR).
